Comparative Pharmacology
Head-to-head clinical analysis: AN DTPA versus FLUORINE F 18.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN DTPA versus FLUORINE F 18.
AN-DTPA vs FLUORINE F-18
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AN-DTPA (pentetate calcium trisodium) is a chelating agent that binds to and removes heavy metals, such as plutonium, americium, curium, and other transuranic elements, from the body. It forms stable complexes with these metals, which are then excreted via the kidneys.
Fluorine-18 decays by positron emission, and the emitted positron annihilates with an electron to produce two 511 keV gamma photons. When incorporated into radiopharmaceuticals such as fludeoxyglucose F-18, it accumulates in metabolically active tissues, enabling PET imaging.
1 gram by intravenous injection or infusion daily for 5 consecutive days, starting immediately after the end of radiotherapy.
2-10 mCi (74-370 MBq) intravenous bolus, single administration for PET imaging.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5-2 hours in patients with normal renal function. Extended significantly in renal impairment (up to 24 hours in anuria).
Physiological half-life is 109.7 minutes (1.83 hours) for fluorine-18 decay by positron emission, with a physical half-life of 109.7 minutes. The biological half-life is dependent on the radiolabeled compound; for [18F]FDG, the effective half-life is approximately 3-4 hours.
Renal: >95% as unchanged drug via glomerular filtration. Biliary/fecal: <5%.
Primarily renal; approximately 95% of administered activity is excreted in urine within 6 hours post-injection. Less than 5% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical